Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk
Annelie Johansson, Domenico Palli, Giovanna Masala, Sara Grioni, Claudia Agnoli, Rosario Tumino, Maria Concetta Giurdanella, Francesca Fasanelli, Carlotta Sacerdote, Salvatore Panico, Amalia Mattiello, Silvia Polidoro, Michael E Jones, Minouk J Schoemaker, Nick Orr, Katarzyna Tomczyk, Nichola Johnson, Olivia Fletcher, Vittorio Perduca, Laura Baglietto Show all
CLINICAL EPIGENETICS | BMC | Published : 2019
BACKGROUND: It is well established that estrogens and other hormonal factors influence breast cancer susceptibility. We hypothesized that a woman's total lifetime estrogen exposure accumulates changes in DNA methylation, detectable in the blood, which could be used in risk assessment for breast cancer. METHODS: An estimated lifetime estrogen exposure (ELEE) model was defined using epidemiological data from EPIC-Italy (n = 31,864). An epigenome-wide association study (EWAS) of ELEE was performed using existing Illumina HumanMethylation450K Beadchip (HM450K) methylation data obtained from EPIC-Italy blood DNA samples (n = 216). A methylation index (MI) of ELEE based on 31 CpG sites was develop..View full abstract
Related Projects (1)
Awarded by Breast Cancer Now PhD scholarship
This work was funded by a Breast Cancer Now PhD scholarship (2014NovPhD403).